Telix Pharmaceuticals Limited Enterprise Value to EBITDA (EV/EBITDA) on July 15, 2025: 90.84

Telix Pharmaceuticals Limited Enterprise Value to EBITDA (EV/EBITDA) is 90.84 on July 15, 2025, a -66.94% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.
  • Telix Pharmaceuticals Limited 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 397.70 on July 15, 2025, which is 337.82% above the current Enterprise Value to EBITDA (EV/EBITDA).
  • Telix Pharmaceuticals Limited 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 79.17 on July 15, 2025, which is -12.84% below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Telix Pharmaceuticals Limited average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 221.92.
Key Data
Date Enterprise Value to EBITDA (EV/EBITDA) Free Cash Flow Yield Dividend Yield Market Capitalization